VTVT · vTv Therapeutics Inc.
Market Cap
$111.01M
Shares
3.95M
Volume · Oct 20
20.54K
Avg daily vol (3M)
60.59K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.85
Open$27.47
Day$27.07–28.56
52W close$20.61–42.72
Avg vol 30d34K
Short int157K · 4.0% float · 3.3d
Short vol48%
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$36.84M
Trailing 12 months
Net income (TTM)
−$4.76M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-25.1%
Trailing 12 months
P / E (TTM)
55.4
Trailing earnings · reciprocal yield 1.8%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+33.2%
Trailing year
Short interest
4.0%
Latest settlement · 3.3 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−11%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
33%
mid-range
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−11%
trailing
YTD return
−30%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $34 — 200d above 50d
Institutional flow
Flat
3 of 45 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.96% of float · ▼ -2.2% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
45 holders — near 3-yr high, broad support
Squeeze score
49
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
Free cash flow
$-25.3M
Balance sheet
$3.3M
net debt
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
33%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $31 › 200d $34 — 200d above 50d
Institutional flow
Flat
3 of 45 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.96% of float · ▼ -2.2% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
45 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $21
Now $28 · 33%
Range high $43
vs 200-day avg -18%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTVT
this stock
vTv Therapeutics Inc.
|
$111.01M | -30.4% | -100.0% | — | 4.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTVT | -1.4% | -10.5% | -11.0% | -9.7% | -30.4% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -0.2% | -9.9% | -19.0% | -10.6% | -43.2% |